Cover Image

Receptor endocytosis and signalling in health and disease. Part A /

Receptor Endocytosis and Signalling in Health and Disease, Volume 194 in the Progress in Molecular Biology and Translational Science, highlights new advances in the field. Chapters in this release include An overview on receptor endocytosis and signaling, Signaling molecules: Importance in health an...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Format: eBook
Language:English
Published: Cambridge, MA : Academic Press, 2023.
Series:Progress in molecular biology and translational science ; v. 194.
Subjects:
Endocytosis.
Cellular signal transduction.
Endocytose.
Transduction du signal cellulaire.
Molecular Biology.
Biophysics.
Life Sciences.
SCIENCE.
Cellular signal transduction
Endocytosis
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Intro
  • Receptor Endocytosis and Signalling in Health and Disease
  • Part A
  • Copyright
  • Contents
  • Contributors
  • Preface
  • Chapter One: An overview of receptor endocytosis and signaling
  • 1. Introduction
  • 2. Role of clathrin in endocytosis
  • 2.1. Clathrin-dependent endocytosis
  • 2.1.1. Role of dynamin in internalization of receptor
  • 2.2. Clathrin-independent endocytosis
  • 3. Role of adaptor protein in internalization of the receptor
  • 4. Subcellular trafficking
  • 5. Receptor trafficking in non-traditional subcellular organelles
  • 6. Role of short-sequence motif in the internalization and trafficking of the receptors
  • 7. Signaling
  • 8. Conclusions and future perspectives
  • Conflict of interest
  • Reference
  • Chapter Two: Emerging tools for studying receptor endocytosis and signaling
  • 1. Introduction
  • 2. Radioligand binding assay
  • 3. Western blot
  • 4. Co-immunoprecipitation and immunoblotting
  • 5. Northern blotting
  • 6. Real-time reverse transcription PCR (qRT PCR)
  • 7. Immunofluorescence and confocal microscopy
  • 8. MicroRNA/small interference RNA
  • 9. Bioassay
  • 10. Conclusion and future perspectives
  • Conflict of interest
  • References
  • Chapter Three: Mas receptor endocytosis and signaling in health and disease
  • 1. Introduction
  • 2. Gene structure and expression of MasR
  • 2.1. MasR signaling
  • 2.2. MasR heteromerization
  • 3. MasR trafficking
  • 4. MasR signaling and receptor trafficking in pathological situations
  • 4.1. Alzheimer´s disease
  • 4.2. Parkinson´s disease (PD)
  • 4.3. Anxiety disorders
  • 5. Concluding remarks
  • References
  • Chapter Four: Regulation of transferrin receptor trafficking by optineurin and its disease-associated mutants
  • 1. Introduction
  • 1.1. Trafficking of TFRC through early and recycling endosomes
  • 2. Role of OPTN in TFRC trafficking and recycling.
  • 3. Glaucoma-associated mutations of OPTN impair TFRC trafficking and recycling
  • 4. Function of OPTN in trafficking of TFRC and associated membrane to autophagosomes
  • 5. Unconventional endocytic trafficking of TFRC
  • 6. Concluding remarks
  • Acknowledgment
  • Author contributions
  • References
  • Chapter Five: The insulin receptor endocytosis
  • 1. Introduction
  • 2. Clathrin-mediated endocytosis of the insulin receptor
  • 2.1. Endocytosis motifs in insulin receptor
  • 2.2. Spindle checkpoint regulators in insulin receptor endocytosis
  • 2.3. Insulin receptor signaling pathways in insulin receptor endocytosis
  • 3. Caveolae-mediated IR endocytosis
  • 3.1. Caveolin and insulin signaling
  • 3.2. Caveolin-binding motifs in insulin receptor
  • 4. Dysfunction of insulin receptor endocytosis
  • 4.1. Animal model
  • 4.2. Obesity, diabetes, and insulin receptor endocytosis
  • 4.3. Insulin receptor endocytosis and gene expression
  • 5. Discussion
  • 6. Conclusion
  • References
  • Chapter Six: VEGFR endocytosis: Implications for angiogenesis
  • 1. Introduction
  • 2. Vascular endothelial growth factors and membrane receptors
  • 2.1. Vascular endothelial growth factors (VEGFs)
  • 2.2. VEGF receptors
  • 2.2.1. VEGFR1
  • 2.2.2. VEGFR2
  • 2.2.3. VEGFR3
  • 2.2.4. VEGF co-receptors
  • 3. VEGFR endocytosis
  • 3.1. Clathrin-dependent endocytosis (CDE)
  • 3.2. Clathrin-independent endocytosis (CIE)
  • 3.2.1. Macropinocytosis
  • 3.2.2. Caveolae, lipid rafts and endocytosis
  • 4. Integration of VEGFR signaling, trafficking and proteolysis
  • 5. VEGFR post-translational modifications
  • 5.1. Phosphorylation
  • 5.2. Ubiquitination
  • 5.3. Other PTMs
  • 6. Implications of VEGFR endocytosis in vascular physiology
  • 6.1. Cell motility and migration
  • 6.2. Cell proliferation and survival
  • 7. Conclusions
  • Acknowledgments
  • References.
  • Chapter Seven: Endocytosis and signaling of angiotensin II type 1 receptor
  • 1. Introduction
  • 2. Ligand-stimulated internalization of AT1 receptor
  • 3. Role of clathrin adaptor proteins in internalization of AT1R
  • 4. Subcellular trafficking of AT1 receptor
  • 5. Role of a short amino acid motif in the internalization and trafficking of AT1R
  • 6. Signaling of AT1 receptor
  • 7. Concluding remarks and future perspectives
  • Conflict of interest
  • References
  • Chapter Eight: B cell receptor (BCR) endocytosis
  • 1. Introduction to the B cell receptor
  • 2. B cell receptor structure
  • 3. B cell receptor signaling and regulation
  • 4. Mechanism of B cell receptor endocytosis
  • 5. Clathrin mediated endocytosis
  • 6. Clathrin independent endocytosis (CIE)
  • 6.1. Phagocytosis
  • 6.2. Other mechanisms of CIE
  • 6.3. Lipid rafts
  • 7. B cell receptor signaling and endocytosis in leukemia and lymphoma
  • 8. Chronic lymphocytic leukemia
  • 9. Diffuse large B cell lymphoma
  • 10. Conclusions
  • Acknowledgments
  • References
  • Chapter Nine: Multifunctional role of the ubiquitin proteasome pathway in phagocytosis
  • 1. Introduction
  • 1.1. A brief history of discovery of phagocytosis
  • 1.2. Phagocytosis: Multifarious pathways
  • 2. The phagocytes
  • 3. Distinct steps of phagocytosis
  • 3.1. Target particle recognition
  • 3.1.1. Fc receptor (FcR) signaling
  • 3.1.2. Complement receptor (CR) signaling
  • 3.2. Phagosome generation
  • 3.2.1. Binding of ligand or particles with receptors
  • 3.2.2. Phagocytic cup formation
  • 3.2.3. Closure of phagocytic cup
  • 3.3. Phagosome maturation
  • 3.3.1. Early phagosomes
  • 3.3.2. Intermediate phagosomes
  • 3.3.3. Late phagosomes and phagolysosomes
  • 4. Phagocytosis: Connection with endoplasmic reticulum (ER)
  • 5. Role of ubiquitin proteasome pathway (UPP) in phagocytosis.
  • 5.1. UPP in phagosome formation and maturation
  • 5.2. UPP in innate immunity and antigen cross presentation
  • 5.3. UPP in removal of apoptotic body and maintenance of tissue homeostasis
  • 5.4. UPP and marking of the phagocytic target
  • 5.5. UPP proteins with unknown roles in phagocytosis
  • 6. Aberrations of UPP in phagocytosis and human diseases
  • 7. Phagosomal machinery of parasites and role of UPP
  • 8. Future perspectives
  • Acknowledgments
  • References
  • Chapter Ten: Receptors of immune cells mediates recognition for tumors
  • 1. Introduction: Inflammation in tumor microenvironment and cancer
  • 2. Tumor initiation
  • 3. Tumor promotion
  • 4. Role of pattern recognition receptors (PRRs) in tumor progression
  • 5. Immune evasion and angiogenesis
  • 5.1. Immune evasion
  • 5.2. Angiogenesis
  • 6. Macrophages function in tumor recognition
  • 6.1. Macrophages in tumor-tissue resident macrophages
  • 6.2. Monocytes derived macrophages
  • 6.3. Macrophages recruitment to the tumor site
  • 6.4. Polarization of macrophages
  • 6.5. Macrophages based immunotherapies
  • 7. Lymphocytes driven immune surveillance
  • 7.1. T cell receptor (TCR) in tumor
  • 7.2. Structure of T cell receptor
  • 7.3. TCR-based immunotherapies/CAR therapies
  • 7.3.1. Chimeric antigen receptors (CARs) T cell therapy
  • 7.3.2. Adoptive cell transfer (ACT)
  • 7.3.3. Immune checkpoint inhibitors
  • 8. Role of B cell receptor in tumor
  • 8.1. BCR-based immunotherapies
  • 9. Natural killer (NK) cells and receptors
  • 9.1. NK cell receptor
  • 9.2. Role of natural killer group 2D (NKG2D)
  • 9.3. Natural cytotoxicity receptors
  • 9.4. NKp80 (KLRF1-killer cell lectin-like receptor subfamily F1)
  • 9.5. Signaling lymphocytic activation molecule (SLAM)-related receptors
  • 9.6. Adhesion molecules and DNA-1
  • 9.7. MHC associated NK cell inhibitory receptors
  • 9.8. NK cell-based therapy.